Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;40(7):1393-1397.
doi: 10.1007/s10096-021-04165-x. Epub 2021 Jan 27.

How to optimize administration of cefoxitin for the treatment of extended spectrum producing Enterobacteriaceae-related infection?

Benoît Pilmis  1   2   3 , Assaf Mizrahi  4   5 , Céline Mory  6 , Alban Le Monnier  4   5   6 , Najoua El Helali  5   6
Affiliations

How to optimize administration of cefoxitin for the treatment of extended spectrum producing Enterobacteriaceae-related infection?

Benoît Pilmis et al. Eur J Clin Microbiol Infect Dis. 2021 Jul.

Abstract

Pharmacological and clinical data regarding cefoxitin for the treatment of ESBL-producing Enterobacteriaceae-related infections are limited. We performed a multicentric prospective cohort study to evaluate continuous/prolonged, or intermittent infusion of cefoxitin. We assessed the plasma concentration as a function of the duration of infusion and then performed a simulation of the percentage of patients who would reach the PK/PD targets, set at 100% ƒT> MIC or 100% ƒT>4 MIC. Eighty-one patients were included. All patients were treated with 6 gr./day. MICs to cefoxitin ranged from 0.5 to 64 mg/L. Sixteen (19.7%) patients were infected with strains with cefoxitin MICs ≥ 8 mg/L. In all patients infected with strains with MICs ≤ 6 mg/L, PK/PD objectives (100% ƒT> MIC) were achieved with prolonged or continuous infusion. In contrast, when MICs were 8 mg/L only, continuous infusion was sufficient to achieve the PK/PD objectives (100% ƒT> MIC). Extended infusion of cefoxitin is necessary for the treatment of non-UTI ESBL-related infections.

Keywords: Cefoxitin; ESBL; PK/PD.

PubMed Disclaimer

References

    1. Jernigan JA, Hatfield KM, Wolford H, Nelson RE, Olubajo B, Reddy SC, et al. Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012-2017. N. Engl. J. Med. 2020;382:1309–19. doi: 10.1056/NEJMoa1914433
    1. Barbier F, Pommier C, Essaied W, Garrouste-Orgeas M, Schwebel C, Ruckly S et al (2016) Colonization and infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure? J Antimicrob Chemother 71:1088–1097. https://doi.org/10.1093/jac/dkv423 - DOI - PubMed
    1. Armand-Lefèvre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppé E et al (2013) Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 57:1488–1495. https://doi.org/10.1128/AAC.01823-12 - DOI - PubMed - PMC
    1. Bouxom H, Fournier D, Bouiller K, Hocquet D, Bertrand X (2018) Which non-carbapenem antibiotics are active against extended-spectrum β-lactamase-producing Enterobacteriaceae? Int. J Antimicrob Agents 52:100–103. https://doi.org/10.1016/j.ijantimicag.2018.03.014 - DOI
    1. Pilmis B, Parize P, Zahar JR, Lortholary O (2014) Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol 33:1263–1265. https://doi.org/10.1007/s10096-014-2094-y - DOI

LinkOut - more resources